

Meeting of the  
General and Plastic Surgery Devices Panel

FDA Advisory Committee Briefing Document

May 2, 2013

**JUVÉDERM VOLUMA™ XC**

**PMA P110033**



Exhibit 1103  
Prolenium v. Allergan

FD-3010-01505-1-1

This page is intentionally left blank

## 1. TABLE OF CONTENTS

---

|        |  |           |
|--------|--|-----------|
| 1.     | <b>TABLE OF CONTENTS</b> .....                           | <b>3</b>  |
| 2.     | <b>LIST OF FIGURES</b> .....                             | <b>5</b>  |
| 3.     | <b>LIST OF TABLES</b> .....                              | <b>7</b>  |
| 4.     | <b>TERMS AND ABBREVIATIONS</b> .....                     | <b>9</b>  |
| 5.     | <b>EXECUTIVE SUMMARY</b> .....                           | <b>11</b> |
| 6.     | <b>CLINICAL NEED FOR MID-FACIAL VOLUMIZING</b> .....     | <b>15</b> |
| 7.     | <b>DERMAL FILLER REGULATORY HISTORY</b> .....            | <b>19</b> |
| 8.     | <b>DEVICE DESCRIPTION</b> .....                          | <b>23</b> |
| 9.     | <b>PRE-CLINICAL TESTING</b> .....                        | <b>27</b> |
| 10.    | <b>VOLUMA-002 CLINICAL STUDY DESIGN</b> .....            | <b>31</b> |
| 10.1   | Overview of Pivotal Study Design.....                    | 32        |
| 10.1.1 | Enrollment .....   | 32        |
| 10.1.2 | Treatment .....  | 33        |
| 10.1.3 | Follow-up.....   | 34        |
| 10.1.4 | Discussion of Study Design.....                          | 36        |
| 10.1.5 | Selection of Study Population .....                      | 38        |
| 10.2   | Effectiveness Measures and Analyses .....                | 39        |
| 10.2.1 | Primary Effectiveness Measure and Analysis.....          | 39        |
| 10.2.2 | Secondary Effectiveness Measurements and Analyses .....  | 41        |
| 10.2.3 | Additional Effectiveness Measurements and Analyses ..... | 42        |
| 10.3   | Safety Measurements .....                                | 45        |
| 10.4   | Analysis Population.....                                 | 46        |
| 10.4.1 | Main Analyses .....                                      | 46        |
| 10.4.2 | Subgroup Analyses .....                                  | 47        |
| 10.5   | Appropriateness of Measurements .....                    | 49        |
| 10.5.1 | MFVDS.....   | 49        |
| 10.5.2 | GAIS, NLFS, and OAFM.....                                | 51        |
| 10.5.3 | Patient Reported Outcomes .....                          | 51        |
| 10.5.4 | 3D Imagery Volume Calculations.....                      | 52        |

|            |   |            |
|------------|---|------------|
| <b>11.</b> | <b>VOLUMA-002 CLINICAL STUDY RESULTS</b> .....                                  | <b>53</b>  |
| 11.1       | Subject Disposition.....  | 53         |
| 11.1.1     | Primary Safety and Effectiveness Period.....                                    | 53         |
| 11.1.2     | Extended Follow-up Period .....   | 55         |
| 11.1.3     | Repeat Treatment and Follow-up.....   | 55         |
| 11.2       | Subject and Treatment Characteristics .....                                     | 55         |
| 11.2.1     | Subject Demographics .....  | 55         |
| 11.2.2     | Treatment Administration .....  | 57         |
| 11.3       | Protocol Deviations .....   | 60         |
| 11.4       | Effectiveness Results.....  | 61         |
| 11.4.1     | Primary Effectiveness Results .....   | 61         |
| 11.4.2     | Secondary Effectiveness Results .....   | 65         |
| 11.4.3     | Effectiveness Beyond Month 6 using MFVDS and GAIS .....                         | 66         |
| 11.4.4     | Additional Effectiveness .....  | 68         |
| 11.4.5     | Subject Self-Assessments .....  | 69         |
| 11.4.6     | Subgroup Analysis .....   | 71         |
| 11.5       | Duration of Effect.....   | 74         |
| 11.6       | Safety Results.....   | 76         |
| 11.6.1     | Common Treatment Responses .....  | 76         |
| 11.6.2     | Adverse Events .....  | 79         |
| 11.6.3     | Subgroup Analyses of Device-Related Adverse Events .....                        | 84         |
| 11.6.4     | Common Treatment Site Responses and Adverse Events After Repeat Treatment ..... | 85         |
| 11.7       | Histopathology Results.....   | 86         |
| <b>12.</b> | <b>POST-APPROVAL PLANS</b> .....  | <b>89</b>  |
| <b>13.</b> | <b>PRODUCT EXPERIENCE WITH VOLUMA™</b> .....                                    | <b>91</b>  |
| 13.1       | Post-Approval Studies World-Wide .....  | 91         |
| 13.2       | Summary of Relevant Literature .....  | 91         |
| 13.3       | Post-Market Surveillance Data on VOLUMA™ XC .....                               | 94         |
| <b>14.</b> | <b>BENEFIT AND RISK ASSESSMENT</b> .....  | <b>97</b>  |
| <b>15.</b> | <b>CONCLUSION</b> .....   | <b>103</b> |
| <b>16.</b> | <b>REFERENCES</b> .....   | <b>105</b> |
| <b>17.</b> | <b>APPENDICES</b> .....   | <b>111</b> |

## 2. LIST OF FIGURES

---

|  |    |
|--|----|
| Figure 1. VOLUMA-002 Clinical Study Design.....                              | 13 |
| Figure 2. Zygomaticomalar Complex .....                                      | 15 |
| Figure 3. Hyaluronic Acid.....   | 23 |
| Figure 4. Chemical Structure of BDDE.....                                    | 24 |
| Figure 5. VOLUMA-002 Clinical Study Design.....                              | 31 |
| Figure 6. Mid-Face Regions Treated .....                                     | 34 |
| Figure 7. Mid-Face Volume Deficit Scale Example Photos .....                 | 40 |
| Figure 8. Subject Diary .....  | 46 |
| Figure 9. Subject Disposition, mITT, and Month 6 Evaluable Populations ..... | 54 |
| Figure 10. Primary Endpoint Analysis.....                                    | 62 |
| Figure 11. GAIS Responder Rate at Month 6.....                               | 65 |
| Figure 12. MFVDS Responder Rates by Mid-Face Region at Month 6.....          | 66 |
| Figure 13. 3D Imaging Calculation of Mid-Face.....                           | 68 |
| Figure 14. Subject GAIS Assessment .....                                     | 69 |
| Figure 15. Subject Satisfaction with Mid-Face Regions .....                  | 70 |
| Figure 16. Satisfaction with Facial Appearance Since Baseline.....           | 70 |
| Figure 17. Duration of Volumizing Effect .....                               | 75 |
| Figure 18. Duration of Volumizing Effect by Volume Injection.....            | 76 |

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.